Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

150%

6 of 4 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

N/A

1(16.7%)

Phase 1

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 4(3)

N/A(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05360056Not ApplicableActive Not Recruiting

Continuous Glucose Monitoring Following Hospital Discharge

Role: lead

NCT01970462Phase 4Terminated

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

Role: lead

NCT01101867Phase 4Completed

Prandial Insulin Dosing in Hospitalized Patients

Role: lead

NCT00812253Phase 2Completed

Intensive Glycemic Control for Congestive Heart Failure Exacerbation

Role: lead

NCT00812487Phase 1Completed

Glycemic Control and Variability for Congestive Heart Failure Exacerbation

Role: lead

NCT01409239Phase 4Completed

Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes

Role: lead

All 6 trials loaded